Kiadis Pharma announces inten­tion to launch an ini­tial pub­lic offer­ing on Euronext Amsterdam and Euronext Brussels

Amsterdam, The Netherlands, June 3, 2015 – Kiadis Pharma B.V. (“Kiadis Pharma”, “Kiadis” or “the Company”), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive cell­based immunother­a­py treat­ments, announces today its inten­tion to raise new funds through an Initial Public Offering and list­ing of the entire share cap­i­tal of a new­ly incor­po­rat­ed hold­ing com­pa­ny on Euronext Amsterdam and Euronext Brussels.

Company high­lights
Innovative cell-ther­a­py for HSCT: Kiadis Pharma devel­ops ATIR™, an inno­v­a­tive cell-ther­a­py for allo­gene­ic hematopoi­et­ic stem cell trans­plan­ta­tion (HSCT). HSCT is gen­er­al­ly regard­ed as the most effec­tive cura­tive approach to blood can­cers and cer­tain inher­it­ed blood dis­or­ders, yet not a viable option for many patients giv­en the risks and lim­i­ta­tions of cur­rent HSCT treat­ments.
Meets sig­nif­i­cant unmet med­ical need: ATIR™ address­es the key risks and lim­i­ta­tions of cur­rent HSCT treat­ments in blood can­cers and inher­it­ed blood dis­or­ders, being: oppor­tunis­tic infec­tions, graft-ver­sus-host-dis­ease (GVHD), can­cer relapse and lim­it­ed donor avail­abil­i­ty. Consequently, ATIR™ enables the safer use of par­tial­ly matched (hap­loiden­ti­cal) fam­i­ly mem­bers as stem cell donors for those patients that would oth­er­wise not find a match­ing donor in time, there­by meet­ing a sig­nif­i­cant unmet med­ical need.
Phase II tri­al for leukaemia: The Company’s lead prod­uct, ATIR™101, is cur­rent­ly in an inter­na­tion­al Phase II tri­al for leukaemia. The tri­al is being con­duct­ed in hos­pi­tals in Belgium, Canada, Germany and the UK. Trial results are expect­ed at the begin­ning of 2016.
Obtained pos­i­tive Phase II inter­im data: Positive inter­im data from the ongo­ing Phase II clin­i­cal tri­al for ATIR™101 were announced in December 2014, sup­port­ing the safe­ty pro­file and show­ing effi­ca­cy of ATIR™101.
Market poten­tial: Kiadis Pharma believes that ATIR™101 has the poten­tial to pro­vide a life­sav­ing ther­a­py to approx­i­mate­ly 19,000 patients in key coun­tries world­wide, with a sub­stan­tial expand­ing pri­ma­ry mar­ket and com­ple­men­tary prod­uct trends.
Second prod­uct for tha­lassemia: Kiadis Pharma’s sec­ond prod­uct, ATIR™201, is expect­ed to be devel­oped for inher­it­ed blood dis­or­ders with an ini­tial focus on tha­lassemia.
Granted EMA man­u­fac­tur­ing qual­i­ty cer­tifi­cate: The Company has a robust, GMP-com­pli­ant man­u­fac­tur­ing process in use in North America and Europe. It is one of five com­pa­nies to have ever been issued an Advanced Therapy Medicinal Product (ATMP) cer­tifi­cate for man­u­fac­tur­ing qual­i­ty and non-clin­i­cal data by the European Medicines Agency (EMA).

Manfred Rüdiger, PhD, Chief Executive Officer of Kiadis Pharma, com­ment­ed: “ATIR™ has the poten­tial to make life-sav­ing trans­plants avail­able to a much larg­er group of patients, sig­nif­i­cant­ly improv­ing suc­cess rates and low­er­ing health­care costs. As we seek to bring this prod­uct through clin­i­cal devel­op­ment and towards autho­ri­sa­tion and com­mer­cial­i­sa­tion, we believe this ini­tial pub­lic offer­ing will sup­port the strong momen­tum already estab­lished by Kiadis.”

Mark Wegter, Chairman of Kiadis Pharma, added: “Kiadis Pharma is oper­at­ing in the very excit­ing immune-oncol­o­gy space and has prod­ucts in devel­op­ment that have the poten­tial to make a huge impact on soci­ety. Thanks to Kiadis there are already many blood can­cer patients still alive that would not have sur­vived with­out the Company’s lead prod­uct, ATIR™101. Kiadis is in my view one of the most excit­ing biotech com­pa­nies in the Netherlands and is now oper­at­ing on a tru­ly inter­na­tion­al stage due to its ongo­ing clin­i­cal tri­al and man­u­fac­tur­ing activ­i­ties in Europe and North America. The intend­ed launch onto the pub­lic mar­kets demon­strates the sig­nif­i­cant progress the expe­ri­enced team at Kiadis has deliv­ered. We are deter­mined to devel­op our prod­ucts through to com­mer­cial­i­sa­tion and build Kiadis into a world­class
bio­phar­ma­ceu­ti­cal leader.”

Clinical devel­op­ment plan
– Subject to the out­come of the ongo­ing Phase II tri­al, which is expect­ed in the first quar­ter of 2016, the Company intends to file for con­di­tion­al approval in the European Union and Canada for ATIR™101 in the fourth quar­ter of 2016.
– A Phase III tri­al for ATIR™101 is envis­aged to start in the sec­ond quar­ter of 2016 which is expect­ed to result in fil­ing for mar­ket­ing autho­ri­sa­tion with EMA, FDA and Health Canada in 2019.
– ATIR™201 is expect­ed to enter clin­i­cal devel­op­ment for tha­lassemia with a Phase I/II tri­al in the first quar­ter of 2016.

The Offering
Kiadis Pharma intends to offer new ordi­nary shares in the IPO of a new­ly incor­po­rat­ed hold­ing com­pa­ny and to seek admis­sion to list­ing and trad­ing of the entire share cap­i­tal of such hold­ing com­pa­ny on Euronext Amsterdam and Euronext Brussels. The Company intends to use the net pro­ceeds of the Offering for the fur­ther clin­i­cal devel­op­ment of ATIR™101 and ATIR™201, pro­duc­tion process opti­mi­sa­tion and automa­tion, work­ing cap­i­tal needs and gen­er­al cor­po­rate pur­pos­es.
Kempen & Co is act­ing as Sole Global Coordinator and Kempen & Co and KBC Securities togeth­er act as Joint Bookrunners. Peel Hunt has been appoint­ed as Co-Manager.

Leave a Reply

Your email address will not be published. Required fields are marked *